Lone Star Funds has acquired Lonza for an undisclosed amount. This corporate acquisition sees Lone Star Funds taking ownership of Lonza, a pioneer and world leader in the Contract Development and Manufacturing Organization (CDMO) industry. The transaction marks a significant change in ownership for the Swiss-founded company, which has been instrumental in advancing pharmaceutical and biotechnology manufacturing for over a century.
Founded in Switzerland in 1897, Lonza established itself as the original CDMO, setting industry standards with its cutting-edge science, smart technology, and lean manufacturing processes. The company is renowned for its ability to transform customers’ breakthrough innovations into viable therapies, manufacturing life-enhancing and life-saving medicines at speed and scale. With a global team of approximately 18,500 colleagues across five continents, Lonza delivers comprehensive, integrated solutions for complex needs, positioning itself as one of the largest Western CDMOs.
The acquisition by Lone Star Funds is strategically aimed at supporting Lonza's continued leadership and growth within the essential CDMO sector. This move is expected to leverage Lonza's established expertise and global footprint, potentially enhancing its operational capabilities and market reach. The focus will be on maintaining Lonza's commitment to quality, safety, and reliability, ensuring the uninterrupted delivery of critical manufacturing services to its global clientele.
Looking ahead, the combined entity is poised to further solidify its position in the dynamic biopharmaceutical landscape. The acquisition is anticipated to provide the resources and strategic direction necessary for Lonza to continue innovating and expanding its capacity to meet the evolving demands of the healthcare industry, ultimately bringing more vital treatments to patients worldwide.